Welcome to our dedicated page for Evaxion AS SEC filings (Ticker: EVAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
When a company’s own research engines are called PIONEER and EDEN, you can expect equally sophisticated disclosures. Evaxion Biotech’s SEC reports are packed with clinical-trial protocols, AI-driven pipeline metrics, and funding milestones that move the share price overnight. For most investors, separating breakthrough data from biotech jargon in a 300-page filing feels impossible.
Stock Titan solves that problem. Our AI reads every new document the moment it hits EDGAR and delivers Evaxion Biotech SEC filings explained simply. Whether you search for “Evaxion Biotech quarterly earnings report 10-Q filing” or need the latest “Evaxion Biotech 8-K material events explained,” you’ll find a clean summary, highlighted risk factors, and direct links to the relevant tables and footnotes.
Wondering what executives do before a big readout? Monitor Evaxion Biotech insider trading Form 4 transactions in real-time and review historical “Evaxion Biotech executive stock transactions Form 4” with one click. Preparing a valuation model? Compare R&D spend and cash runway through the “Evaxion Biotech annual report 10-K simplified.” Curious about board pay? The Evaxion Biotech proxy statement executive compensation section is extracted and translated into plain language. Each report also includes an Evaxion Biotech earnings report filing analysis that calls out revenue recognition changes, trial expense shifts, and partner milestones.
- AI-powered summaries and red-flag alerts
- Real-time “Evaxion Biotech Form 4 insider transactions” feeds
- Side-by-side trends across 10-Q, 10-K and 8-K forms
- Instant keyword search across every exhibit
Stop paging through dense biotech language—start understanding Evaxion Biotech SEC documents with AI and make timely, informed decisions.
Evaxion A/S furnished a press release dated September 25, 2025 announcing that it has out-licensed its vaccine candidate EVX-B3 to MSD. The Form 6-K states the press release is filed as Exhibit 99.1 and that this report is incorporated by reference into several of Evaxion's registration statements, including Forms S-8, F-3 and multiple F-1 filings. The filing provides notice of the transaction but includes no financial terms, milestone schedules, or operational details within this report.
Evaxion A/S furnished a Form 6-K reporting that it issued a press release titled "Evaxion to present at several conferences during the second half of 2025" and furnished that press release as Exhibit 99.1 to the report. The company states this Form 6-K is incorporated by reference into multiple registration statements, including Forms S-8, F-3 and several Form F-1 filings, such that the press release and related disclosure become part of those registration statements to the extent not superseded. The report is signed on behalf of the registrant by Birgitte Rønø, Interim Chief Executive Officer.
Evaxion A/S, a clinical-stage TechBio company using AI-Immunology, furnished a press release announcing it will provide a business update and publish its second-quarter 2025 financial results on August 14, 2025. The Form 6-K states the press release is furnished as Exhibit 99.1 to the filing.
The filing itself contains no financial figures, operational metrics, or transaction details; it serves to notify investors of the timing and availability of the forthcoming update and results announcement.
Evaxion A/S (NASDAQ: EVAX) filed a Form 6-K on 11 July 2025 to furnish a press release announcing that the Company has finalized an agreement with the European Investment Bank (EIB) to convert existing debt into equity. The press release, provided as Exhibit 99.1, is the only substantive disclosure contained in the filing. No additional terms, financial amounts, or timing details are included in the 6-K.
Evaxion (NASDAQ: EVAX) filed a Form 6-K furnishing a June 25, 2025 press release entitled “Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus.” The document reports that the clinical-stage TechBio company is adding a Group A Strep prophylactic candidate to its AI-Immunology-powered vaccine portfolio.
The submission is informational only: it contains no financial statements, guidance, capital-raising details, or clinical timelines. The press release (Exhibit 99.1) is incorporated by reference into multiple outstanding registration statements (Forms S-8, F-1 and F-3), ensuring that future prospectuses automatically reflect the new program.
There are no disclosures of changes in management, litigation, risk factors, or business strategy beyond the stated pipeline expansion. Accordingly, the filing signals strategic breadth but offers limited quantifiable data for investors to model near-term cash requirements or milestones.
FAQ
What is the current stock price of Evaxion AS (EVAX)?
What is the market cap of Evaxion AS (EVAX)?
